Biography
Since 2005 - a CSO at XENOTOX, Inc. Have a medical background (M.D., 1970), Ph.D. in Biochemistry (1973), D.Sc. in Molecular Toxicology (1983). Hold progressively responsible positions: Group Leader (74-79), Head of the Laboratory (1979-87), Department Chair (1987-91), all at Russian Academy of Science. In the US: a Senior Scientist at NCI, NIH (1991-95), Professor (since 2010 - visiting) at Mount Sinai School of Medicine (1995-to date). Author of 5 monographs and 250+ peer reviewed publications. By using enzyme-kinetic and inhibitory analyses, pioneered in revealing TCDD-induced CYP1B1 (FEBS Letters, 1987). Invented the recombinant and TCDD-induced microsomal and isolated monooxygenase isoforms CYP1A1 and CYP1A2, to study regulatory effects of bioflavonoids on procarcinogens metabolism in humans (BBA, 1994). Since the discovery of trans-activation effect of TCDD on HIV-1 (BBRC, 1991), have established Xenobiotical Virology, a biomedical discipline dealing with mechanisms of dioxin effects on DRE-containing genes of human viruses, transcription factors and cytokines linked to inflammation and malignancy pathways.
Research Interest
Viruses
Biography
Ronald Moss, M.D. has served as the Chief Executive Officer of Ansun Biopharma, Inc. since October 2012, and before that, served as both interim CEO and Executive Vice President of Clinical Development and Medical Affairs at Ansun from 2008 to 2012. Dr. Moss has held various executive positions in the pharmaceutical industry for over 20 years and has played a pivotal role in successfully leading companies through the complexities of drug and vaccine development. Dr. Moss has been involved in drug and vaccine development of products in Infectious Disease, Allergy, Neurology, Dermatology, Oncology, Respiratory, Transplant, and Autoimmunity in both large pharmaceutical and biotechnology companies, including roles at Aventis, Immune Response, Merck, Telos and Vical. He has also authored over 70 scientific publications. Prior to joining industry, he received his M.D. degree from Chicago Medical School, completed a residency in pediatrics at SUNY Stony Brook and completed a fellowship at the National Institutes of Health. He is double boarded in Pediatrics and Allergy and Immunology. He is also a Fellow of the American Academy and American College of Allergy and Immunology
Research Interest
Infectious Disease, Allergy, Neurology, Dermatology, Oncology, Respiratory, Transplant, and Autoimmunity.
Biography
Professor Ting-Chao Chou received MS degree in Pharmacology from National Taiwan University College of Medicine; Ph.D. from Yale University, and Postdoctoral Fellowship at Johns Hopkins University School of Medicine. Joined Memorial Sloan-Kettering Cancer Center (MSKCC), became Member 1988-96, and a Professor of Pharmacology at Cornell University Graduate School of Medical Sciences, 1988-2000. He is Honorary Professor at Chinese Academy of Medical Sciences, Beijing and five other universities. He focused in the new drug discovery as the Director of Preclinical Pharmacology Core at MSKCC, where he retired on June1, 2013. His 273 scientific articles have been cited by 15,606 papers (as of 8.31.2014). (Thomson Reuters Web of Science: www.researcherid.com/rid/B-4111-2009). Prof. Chou introduced the “Unified Theory of the Median-Effect Equation of the Mass-Action Lawâ€, and with Prof. Paul Talalay (JHU) in 1984, created the “Combination Index Theorem†for multiple entity dynamics. For one article alone (Chou TC and Talalay P., Adv Enz Regul 22:27-55, 1984), cited by 3,218 articles published in 599 biomedical journals and has become one of four the most broadly cited theoretical articles by journals of all time. Chou's dynamics equations and theory has been extended to illustrate the ancient Chinese philosophy and to advocate Econo-Green Bio-Research. He is Inventor/Co-inventor of 36 U.S. Patents, on Editorial Board of five international scientific journals, and is the founder of PD Science, LLC.
Research Interest
Virology